Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, and systemic inflammation. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant effects on...

Descrición completa

Detalles Bibliográficos

Principais autores:	Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-07-01
Series:	Frontiers in Endocrinology
Assuntos:	fatty liver index (FLI) Inflammation metabolic dysfunction–associated steatotic liver disease (MASLD) obesity tirzepatide
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1855886/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!